JP2013502913A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013502913A5 JP2013502913A5 JP2012526072A JP2012526072A JP2013502913A5 JP 2013502913 A5 JP2013502913 A5 JP 2013502913A5 JP 2012526072 A JP2012526072 A JP 2012526072A JP 2012526072 A JP2012526072 A JP 2012526072A JP 2013502913 A5 JP2013502913 A5 JP 2013502913A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- abm
- chain variable
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23850509P | 2009-08-31 | 2009-08-31 | |
| US61/238,505 | 2009-08-31 | ||
| PCT/EP2010/062527 WO2011023787A1 (en) | 2009-08-31 | 2010-08-27 | Affinity-matured humanized anti cea monoclonal antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013502913A JP2013502913A (ja) | 2013-01-31 |
| JP2013502913A5 true JP2013502913A5 (enExample) | 2013-04-18 |
| JP5744872B2 JP5744872B2 (ja) | 2015-07-08 |
Family
ID=42985489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012526072A Expired - Fee Related JP5744872B2 (ja) | 2009-08-31 | 2010-08-27 | 親和性成熟ヒト化抗ｃｅａモノクローナル抗体 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9068008B2 (enExample) |
| EP (1) | EP2473532B1 (enExample) |
| JP (1) | JP5744872B2 (enExample) |
| KR (1) | KR101528013B1 (enExample) |
| CN (1) | CN102741293B (enExample) |
| AR (1) | AR078111A1 (enExample) |
| AU (1) | AU2010288469A1 (enExample) |
| BR (1) | BR112012003983A2 (enExample) |
| CA (1) | CA2770174A1 (enExample) |
| CL (1) | CL2012000551A1 (enExample) |
| CO (1) | CO6491105A2 (enExample) |
| CR (1) | CR20120087A (enExample) |
| EC (1) | ECSP12011698A (enExample) |
| IL (1) | IL218038A0 (enExample) |
| MA (1) | MA33536B1 (enExample) |
| MX (1) | MX339608B (enExample) |
| PE (1) | PE20121552A1 (enExample) |
| RU (1) | RU2570554C2 (enExample) |
| SG (1) | SG178567A1 (enExample) |
| TW (1) | TW201121994A (enExample) |
| WO (1) | WO2011023787A1 (enExample) |
| ZA (1) | ZA201200954B (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5992710A (ja) * | 1982-11-16 | 1984-05-29 | 関西電力株式会社 | 直接水冷線路の立坑部の布設方法 |
| KR20100018071A (ko) | 2001-08-03 | 2010-02-16 | 글리카트 바이오테크놀로지 아게 | 항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체 |
| BR112013019083A2 (pt) | 2011-02-10 | 2017-04-04 | Roche Glycart Ag | combinação de (a) um imunoconjugado, composição farmacêutica, uso de (a) um imunoconjugado, método de tratamento de uma doença em um individuo, método de estímulo de função celular efetora em um indivíduo e kit destinado ao tratamento de uma doença. |
| HUE029139T2 (hu) | 2011-02-10 | 2017-02-28 | Roche Glycart Ag | Mutáns interleukin-2 polipeptidek |
| HRP20180147T1 (hr) * | 2011-03-02 | 2018-02-23 | Roche Glycart Ag | Cea protutijela |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| DK2748202T3 (en) | 2011-08-23 | 2018-09-17 | Roche Glycart Ag | BISPECIFIC ANTI-BINDING MOLECULES |
| CA2844540C (en) | 2011-08-23 | 2018-10-16 | Roche Glycart Ag | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| WO2013026833A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| WO2013054320A1 (en) * | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
| GB201213858D0 (en) | 2012-08-03 | 2012-09-19 | Mab Design Ltd | Method |
| EP3434695B1 (en) | 2012-08-07 | 2020-12-02 | Roche Glycart AG | Improved immunotherapy |
| CN104704004B (zh) | 2012-10-08 | 2019-12-31 | 罗切格利卡特公司 | 包含两个Fab片段的无Fc的抗体及使用方法 |
| KR20150122203A (ko) | 2013-02-26 | 2015-10-30 | 로슈 글리카트 아게 | T 세포 활성화 이중특이적 항원 결합 분자 |
| EA031214B1 (ru) | 2013-02-26 | 2018-12-28 | Роше Гликарт Аг | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки |
| WO2014131694A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
| CA2946262C (en) | 2014-04-27 | 2022-07-26 | Ccam Biotherapeutics Ltd. | Humanized antibodies against ceacam1 |
| CN106661120B (zh) | 2014-08-04 | 2021-10-01 | 豪夫迈·罗氏有限公司 | 双特异性t细胞活化性抗原结合分子 |
| JP6944369B2 (ja) | 2014-11-20 | 2021-10-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｔ細胞活性化二重特異性抗原結合分子ｃｄ３ ａｂｄ葉酸受容体１（ｆｏｌｒ１）及びｐｄ−１軸結合アンタゴニストの併用療法 |
| PT3221357T (pt) | 2014-11-20 | 2020-07-28 | Hoffmann La Roche | Cadeias leves comuns e métodos de utilização |
| MA40972B1 (fr) | 2014-11-20 | 2020-11-30 | Hoffmann La Roche | Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t ciblant folr1 et cd3 |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| MA43025A (fr) | 2015-10-02 | 2021-05-26 | Hoffmann La Roche | Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t anti-ceaxcd3 |
| PL3387015T3 (pl) | 2015-12-09 | 2022-02-14 | F. Hoffmann-La Roche Ag | Przeciwciało anty-CD20 typu II do ograniczania tworzenia przeciwciał przeciwlekowych |
| JP6949030B2 (ja) | 2016-01-08 | 2021-10-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｐｄ−１軸結合アンタゴニスト及び抗ｃｅａ／抗ｃｄ３二重特異性抗体を用いたｃｅａ陽性がんの治療方法 |
| RS64266B1 (sr) | 2016-03-22 | 2023-07-31 | Hoffmann La Roche | Bispecifični molekul koji aktivira t ćeliju koji se aktivira proteazom |
| CN107663240B (zh) * | 2016-07-29 | 2021-01-12 | 中国人民解放军第四军医大学 | 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用 |
| ES2897217T3 (es) | 2016-09-30 | 2022-02-28 | Hoffmann La Roche | Anticuerpos biespecíficos frente a p95HER2 |
| CA3089287A1 (en) | 2018-02-08 | 2019-08-15 | Genentech, Inc. | Bispecific antigen-binding molecules and methods of use |
| TWI804572B (zh) | 2018-02-09 | 2023-06-11 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
| WO2020259550A1 (zh) * | 2019-06-26 | 2020-12-30 | 江苏恒瑞医药股份有限公司 | 抗cea抗体及其应用 |
| CA3141378A1 (en) | 2019-06-26 | 2020-12-30 | F. Hoffmann-La Roche Ag | Fusion of an antibody binding cea and 4-1bbl |
| CN110862456B (zh) * | 2019-09-23 | 2021-04-09 | 华道(上海)生物医药有限公司 | 一种抗癌胚抗原的抗体及其制备方法和用途 |
| CN110713539B (zh) * | 2019-09-23 | 2021-04-16 | 华道(上海)生物医药有限公司 | 一种抗癌胚抗原的抗体及其制备方法和用途 |
| BR112022025856A2 (pt) | 2020-06-19 | 2023-01-10 | Hoffmann La Roche | Anticorpo que se liga a cd3 e cd19, polinucleotídeo isolado, célula hospedeira, método de produção de um anticorpo que se liga a cd3 e cd19, composição farmacêutica, uso do anticorpo, método para tratar uma doença em um indivíduo e invenção |
| CA3188867A1 (en) | 2020-08-20 | 2022-02-24 | Xueyin Wang | Compositions and methods for treating ceacam positive cancers |
| KR102859548B1 (ko) | 2020-08-20 | 2025-09-12 | 에이투 바이오쎄라퓨틱스, 인크. | 메소텔린 양성 암을 치료하기 위한 조성물 및 방법 |
| KR20240005691A (ko) | 2021-04-30 | 2024-01-12 | 에프. 호프만-라 로슈 아게 | 항-cd20/항-cd3 이중특이적 항체 및 항-cd79b 항체 약물 접합체를 이용한 병용 치료를 위한 투약 |
| TW202307004A (zh) * | 2021-05-21 | 2023-02-16 | 英屬開曼群島商百濟神州有限公司 | 抗ｃｅａ抗體及使用方法 |
| CN118946580A (zh) * | 2022-01-27 | 2024-11-12 | 詹森生物科技公司 | 增强的蛋白质组合物 |
| JP2025510678A (ja) | 2022-03-23 | 2025-04-15 | シンアフィックス ビー．ブイ． | カルシノエンビロニック抗原を発現する腫瘍を標的化するための抗体コンジュゲート |
| TW202506733A (zh) | 2023-06-12 | 2025-02-16 | 美商安進公司 | 淋巴毒素β受體促效劑結合蛋白 |
| WO2025257185A1 (en) * | 2024-06-11 | 2025-12-18 | Abcely | Humanized anti-human-carcinoembryonic antigen antibody |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| ATE203168T1 (de) * | 1992-05-07 | 2001-08-15 | Nycomed Imaging As | Komplexbildnermittel und zielimmunoreagenzien |
| GB9317423D0 (en) * | 1993-08-21 | 1993-10-06 | Imp Cancer Res Tech | Monoclonal antibodies |
| GB9324807D0 (en) | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| US6417337B1 (en) | 1996-10-31 | 2002-07-09 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| ES2420835T3 (es) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de las moléculas inmunofuncionales |
| US6815184B2 (en) | 2000-07-31 | 2004-11-09 | Biolex, Inc. | Expression of biologically active polypeptide in duckweed |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US6815175B2 (en) * | 2001-03-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| KR20100018071A (ko) | 2001-08-03 | 2010-02-16 | 글리카트 바이오테크놀로지 아게 | 항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체 |
| MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US8932825B2 (en) | 2001-12-27 | 2015-01-13 | Glycofi Inc. | Method to engineer mammalian-type carbohydrate structures |
| US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
| US20070148171A1 (en) * | 2002-09-27 | 2007-06-28 | Xencor, Inc. | Optimized anti-CD30 antibodies |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| KR101070518B1 (ko) | 2002-03-19 | 2011-10-05 | 스티칭 디엔스트 랜드보위쿤디그 온데조에크 | 식물에서의 ｇｎｔⅲ 발현 |
| CA2481658A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to fcy receptor iiia |
| EP1500698B1 (en) | 2002-04-09 | 2011-03-30 | Kyowa Hakko Kirin Co., Ltd. | Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
| EP1502603A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM |
| JPWO2003085118A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
| JPWO2003085107A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | ゲノムが改変された細胞 |
| US7232888B2 (en) | 2002-07-01 | 2007-06-19 | Massachusetts Institute Of Technology | Antibodies against tumor surface antigens |
| JP5138867B2 (ja) * | 2002-08-01 | 2013-02-06 | イミューノメディクス、インコーポレイテッド | α−フェトタンパク質Ｉｍｍｕ３１抗体および融合タンパク質ならびにその使用方法 |
| ES2347325T3 (es) | 2002-09-12 | 2010-10-28 | Greenovation Biotech Gmbh | Metodo de produccion de proteinas. |
| JP4559358B2 (ja) | 2002-12-20 | 2010-10-06 | グリーンオベーション バイオテク ゲーエムベーハー | コケ細胞における異種グリコシル化タンパク質の産生 |
| JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス，インコーポレーテッド | 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法 |
| CZ308720B6 (cs) | 2003-01-22 | 2021-03-24 | Roche Glycart Ag | Fúzní konstrukty a jejich použití pro přípravu protilátek se zvýšenou vazebnou afinitou k receptorům Fc a efektorovou funkcí |
| JP4889493B2 (ja) * | 2003-05-14 | 2012-03-07 | ドマンティス リミテッド | ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法 |
| HRP20180147T1 (hr) * | 2011-03-02 | 2018-02-23 | Roche Glycart Ag | Cea protutijela |
-
2010
- 2010-08-27 EP EP10745651.9A patent/EP2473532B1/en active Active
- 2010-08-27 JP JP2012526072A patent/JP5744872B2/ja not_active Expired - Fee Related
- 2010-08-27 KR KR1020127008265A patent/KR101528013B1/ko not_active Expired - Fee Related
- 2010-08-27 SG SG2012013306A patent/SG178567A1/en unknown
- 2010-08-27 PE PE2012000266A patent/PE20121552A1/es not_active Application Discontinuation
- 2010-08-27 BR BR112012003983-0A patent/BR112012003983A2/pt not_active Application Discontinuation
- 2010-08-27 CA CA2770174A patent/CA2770174A1/en not_active Abandoned
- 2010-08-27 RU RU2012112340/10A patent/RU2570554C2/ru active
- 2010-08-27 AU AU2010288469A patent/AU2010288469A1/en not_active Abandoned
- 2010-08-27 CN CN201080048622.1A patent/CN102741293B/zh not_active Expired - Fee Related
- 2010-08-27 MX MX2012002461A patent/MX339608B/es active IP Right Grant
- 2010-08-27 WO PCT/EP2010/062527 patent/WO2011023787A1/en not_active Ceased
- 2010-08-30 TW TW099129130A patent/TW201121994A/zh unknown
- 2010-08-30 AR ARP100103166A patent/AR078111A1/es not_active Application Discontinuation
- 2010-08-31 US US12/872,908 patent/US9068008B2/en active Active
-
2012
- 2012-01-30 CO CO12014021A patent/CO6491105A2/es not_active Application Discontinuation
- 2012-02-08 ZA ZA2012/00954A patent/ZA201200954B/en unknown
- 2012-02-09 IL IL218038A patent/IL218038A0/en unknown
- 2012-02-20 CR CR20120087A patent/CR20120087A/es unknown
- 2012-02-27 MA MA34650A patent/MA33536B1/fr unknown
- 2012-02-28 EC ECSP12011698 patent/ECSP12011698A/es unknown
- 2012-02-29 CL CL2012000551A patent/CL2012000551A1/es unknown
-
2015
- 2015-05-26 US US14/721,795 patent/US20160075795A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013502913A5 (enExample) | ||
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| TWI771361B (zh) | 人程序性死亡受體pd-1的單株抗體及其片段 | |
| JP2020501531A5 (enExample) | ||
| CN103030695B (zh) | 抗c‑Met人源化抗体及含其的预防或治疗癌症用的药物组合物 | |
| JP2014527814A5 (enExample) | ||
| JP2010504755A5 (enExample) | ||
| WO2022171100A1 (zh) | Gpc3人源化抗体及其应用 | |
| CN121108344A (zh) | 抗cd3抗体以及其用途 | |
| WO2022228183A1 (zh) | 抗siglec15抗体及其制备方法和用途 | |
| JP2025503513A (ja) | Ｃｄ３を標的にする抗体、多特異性抗体、およびその使用 | |
| CN113227148A (zh) | 抗gpc3抗体、其抗原结合片段及其医药用途 | |
| CN112805297B (zh) | 抗人类pd-l1抗体及其用途 | |
| AU2021292231A1 (en) | CD38 antibodies for the treatment of human diseases | |
| WO2023222135A9 (en) | A method of treating solid tumor | |
| US20240166768A1 (en) | Anti-matrix metalloproteinase-14 antibodies for the treatment of cancer | |
| TWI908815B (zh) | 用於人類疾病之治療的ｃｄ３８抗體 | |
| EP4534562A1 (en) | Bispecific antibody and application thereof | |
| WO2018202794A1 (en) | Antibodies against carcinoembryonic antigen for cancer therapy and diagnosis | |
| HK40119299A (zh) | 抗cd73抗体及其用途 | |
| JP7162011B2 (ja) | 癌糖ペプチドに対するモノクローナルおよびヒト化抗体 | |
| TW202313690A (zh) | 一種抗b7-h4抗體及其製備方法和應用 | |
| TW202521571A (zh) | 抗ｃｅａｃａｍ５抗體及其用途 | |
| IL285313A (en) | Antibodies for cancer treatment | |
| TW202540198A (zh) | 雙特異性抗體樣蛋白以及彼之製造及使用方法 |